{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361418521194006912.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/hep.26301"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.26301"}},{"identifier":{"@type":"URI","@value":"https://journals.lww.com/01515467-201311000-00005"}}],"dc:title":[{"@value":"Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:sec>\n            <jats:title/>\n            <jats:p>\n                                 <jats:bold>Entecavir is a potent antiviral agent with high genetic barrier to resistance, hence it is currently recommended as first-line antiviral therapy for chronic hepatitis B (CHB). The aim of this study was to investigate the efficacy of entecavir on clinical outcomes and deaths. It was a retrospective-prospective cohort study based on two cohorts of patients. The entecavir cohort included consecutive CHB patients who had received entecavir 0.5 mg/day for at least 12 months. The historical control cohort included untreated patients recruited since 1997 who underwent routine clinical care. The primary outcome was the 5-year cumulative probability of hepatic events, defined as any cirrhotic complications, hepatocellular carcinoma (HCC), and/or liver-related mortality. A total of 1,446 entecavir-treated patients (72% men; age, 51 ± 12 years; follow-up, 36 ± 13 months) and 424 treatment-naïve patients (65% men; age, 41 ± 13 years; follow-up, 114 ± 31 months) were studied. Overall, there was no difference in hepatic events between the entecavir and control cohorts. Among patients with liver cirrhosis (482 entecavir-treated, 69 treatment-naïve), entecavir-treated patients had reduced risks of all clinical outcomes when compared with treatment-naïve patients with cirrhosis after adjusted for model for end-stage liver disease score: hepatic events (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.34-0.78;</jats:bold>\n                                 <jats:bold>\n                                    P\n                                 </jats:bold>\n                                 <jats:bold>= 0.002), HCC (HR, 0.55; 95% CI, 0.31-0.99;</jats:bold>\n                                 <jats:bold>\n                                    P\n                                 </jats:bold>\n                                 <jats:bold>= 0.049), liver-related mortality (HR, 0.26; 95% CI, 0.13-0.55;</jats:bold>\n                                 <jats:bold>\n                                    P\n                                 </jats:bold>\n                                 <jats:bold>< 0.001), and all-cause mortality (HR, 0.34; 95% CI, 0.18-0.62;</jats:bold>\n                                 <jats:bold>\n                                    P\n                                 </jats:bold>\n                                 <jats:bold>< 0.001). Entecavir-treated patients with cirrhosis who failed to achieve undetectable hepatitis B virus DNA (105/482 [22%]) had comparable risk of hepatic events as the untreated patients.</jats:bold>\n                              </jats:p>\n          </jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:</jats:title>\n            <jats:p>\n                                 <jats:bold>Entecavir therapy reduces the risks of hepatic events, HCC, liver-related and all-cause mortality of CHB patients with liver cirrhosis in 5 years, particularly among those who had maintained viral suppression. (Hepatology 2013;58:1537–1547)</jats:bold>\n                              </jats:p>\n          </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381418521194006921","@type":"Researcher","foaf:name":[{"@value":"Grace Lai-Hung Wong"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006913","@type":"Researcher","foaf:name":[{"@value":"Henry Lik-Yuen Chan"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006915","@type":"Researcher","foaf:name":[{"@value":"Christy Wing-Hin Mak"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006920","@type":"Researcher","foaf:name":[{"@value":"Stanley King-Yeung Lee"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006918","@type":"Researcher","foaf:name":[{"@value":"Zoe Man-Yi Ip"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006922","@type":"Researcher","foaf:name":[{"@value":"Andrew Ting-Ho Lam"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006919","@type":"Researcher","foaf:name":[{"@value":"Henry Wing-Hang Iu"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006912","@type":"Researcher","foaf:name":[{"@value":"Joyce May-Sum Leung"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006914","@type":"Researcher","foaf:name":[{"@value":"Jennifer Wing-Yan Lai"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006784","@type":"Researcher","foaf:name":[{"@value":"Angeline Oi-Shan Lo"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006916","@type":"Researcher","foaf:name":[{"@value":"Hoi-Yun Chan"}]},{"@id":"https://cir.nii.ac.jp/crid/1381418521194006917","@type":"Researcher","foaf:name":[{"@value":"Vincent Wai-Sun Wong"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"02709139"}],"prism:publicationName":[{"@value":"Hepatology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2013-11","prism:volume":"58","prism:number":"5","prism:startingPage":"1537","prism:endingPage":"1547"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1.1","http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fhep.26301"},{"@id":"https://journals.lww.com/01515467-201311000-00005"}],"createdAt":"2013-02-06","modifiedAt":"2024-12-01","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360002215482011904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231260693376","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235963698176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1360017282231744768","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025430195451136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283695965035264","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360286989677632000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181466116736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of long-term entecavir treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580232188278784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Possible biological mechanisms of entecavir <i>versus</i> tenofovir disoproxil fumarate on reducing the risk of hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584341837696000","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Usefulness of the Fibrosis‐4 index and alanine aminotransferase at 1 year of nucleos(t)ide analog treatment for prediction of hepatocellular carcinoma in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588379379166848","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Circulating thrombospondin 2 as a predictor of hepatocellular carcinoma in hepatitis B patients undergoing nucleos(t)ide analog therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643463251456","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865814743789568","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865815502085504","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Integrated Predictors by Propensity Scoring With Tumor Markers and Plasma Levels of microRNA-21-5p, IL-17, and IL-10 Complement Early Detection of Hepatocellular Carcinoma in Patients With Liver Cirrhosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679771619840","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two cases of acute hepatitis due to hepatitis E virus that are indigenous to Kitakyushu: a case report"},{"@language":"ja","@value":"北九州に土着したE型肝炎ウイルス株による急性肝炎の2例"},{"@value":"B型肝炎治療ガイドライン(第1.1版)"},{"@language":"ja-Kana","@value":"Bガタ カンエン チリョウ ガイドライン(ダイ1.1ハン)"},{"@language":"ja-Kana","@value":"キタキュウシュウ ニ ドチャク シタ Eガタ カンエンウイルスカブ ニ ヨル キュウセイ カンエン ノ 2レイ"},{"@value":"Guidelines for the management of hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1390302646673945600","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/hep.26301"},{"@type":"CROSSREF","@value":"10.1007/s12072-017-9799-9_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1007/s00535-014-1010-7_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1128/aac.00725-17_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1002/jmv.28210_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.3390/cells14060428_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.4254/wjh.v7.i22.2404_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1002/hep.30956_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1111/hepr.12269_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1007/s12072-015-9647-8_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1111/jgh.16178_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1111/hepr.13957_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1038/s41598-024-76532-5_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1136/gutjnl-2016-312653_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.2957/kanzo.54.402_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.35772/ghm.2024.01008_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1097/hep.0000000000000459_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"},{"@type":"CROSSREF","@value":"10.1177/15330338231212084_references_DOI_6KMWtyOw8YWF8wAYxRNtAQfb1OQ"}]}